GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (OTCPK:RTNXF) » Definitions » Debt-to-Asset

RTNXF (Renalytix) Debt-to-Asset : 1.72 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Renalytix Debt-to-Asset?

Renalytix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.15 Mil. Renalytix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.10 Mil. Renalytix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $4.79 Mil. Renalytix's debt to asset for the quarter that ended in Sep. 2024 was 1.72.


Renalytix Debt-to-Asset Historical Data

The historical data trend for Renalytix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Debt-to-Asset Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial 0.02 - 0.25 0.40 1.07

Renalytix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.39 1.07 1.07 1.72

Competitive Comparison of Renalytix's Debt-to-Asset

For the Health Information Services subindustry, Renalytix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Renalytix's Debt-to-Asset falls into.



Renalytix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Renalytix's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Renalytix's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix  (OTCPK:RTNXF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Renalytix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Renalytix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix Business Description

Traded in Other Exchanges
Address
2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.